| Summary of Earnings Per Share |
| | | | | | | | | | | | | | | | | | | | | | | | | | | Table 7.1: EPS | | | Three months ended | | Six months ended | (in thousands, except share and per share data) | | June 30, 2026 | | June 30, 2025 | | June 30, 2026 | | June 30, 2025 | | Net income | | $ | 19,399 | | | $ | 14,508 | | | $ | 38,020 | | | $ | 27,619 | | | | | | | | | | | | Basic weighted average common shares outstanding | | 21,273,902 | | | 21,225,831 | | | 21,263,551 | | | 21,217,900 | | | Add: Dilutive effects of assumed vesting of restricted and performance-based stock | | 65,001 | | | 43,434 | | | 68,178 | | | 43,570 | | | Total dilutive weighted average common shares outstanding | | 21,338,903 | | | 21,269,265 | | | 21,331,729 | | | 21,261,470 | | | Earnings per common share: | | | | | | | | | | Basic EPS | | $ | 0.91 | | | $ | 0.68 | | | $ | 1.79 | | | $ | 1.30 | | | Diluted EPS | | $ | 0.91 | | | $ | 0.68 | | | $ | 1.78 | | | $ | 1.30 | |
|
| Summary of Nonvested Restricted Stock Shares |
Table 7.2 summarizes activity related to restricted shares for the periods indicated. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Table 7.2: Unvested RSA Activity | | | For the three months ended June 30, | | For the six months ended June 30, | | 2026 | | 2025 | | 2026 | | 2025 | | Shares | | Weighted Average Grant Date Fair Value | | Shares | | Weighted Average Grant Date Fair Value | | Shares | | Weighted Average Grant Date Fair Value | | Shares | | Weighted Average Grant Date Fair Value | | Beginning of the period balance | | 116,103 | | | $ | 24.89 | | | 111,786 | | | $ | 22.08 | | | 124,747 | | | $ | 23.25 | | | 120,577 | | | $ | 21.36 | | | Shares granted | | 26,711 | | | 42.00 | | | 31,756 | | | 27.55 | | | 35,477 | | | 41.38 | | | 42,241 | | | 28.38 | | | Shares vested | | (22,053) | | | 22.72 | | | (14,094) | | | 20.00 | | | (39,463) | | | 22.39 | | | (33,037) | | | 21.33 | | | Shares forfeited | | — | | | — | | | — | | | — | | | — | | | — | | | (333) | | | 21.97 | | | End of the period balance | | 120,761 | | | $ | 29.07 | | | 129,448 | | | $ | 23.65 | | | 120,761 | | | $ | 29.07 | | | 129,448 | | | $ | 23.65 | |
Table 7.3 summarizes information about unvested PSUs. The weighted average grant date fair value is based on the fair value at the time of grant. The vesting of PSUs is subject to achievement of specified performance targets and continued employment. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Table 7.3: Unvested PSU Activity | | | For the three months ended June 30, | | For the six months ended June 30, | | | 2026 | | 2025 | | 2026 | | 2025 | | Shares | | Weighted Average Grant Date Fair Value | | Shares | | Weighted Average Grant Date Fair Value | | Shares | | Weighted Average Grant Date Fair Value | | Shares | | Weighted Average Grant Date Fair Value | | Beginning of the period balance | | 23,110 | | | $ | 31.15 | | | — | | | $ | — | | | 23,110 | | | $ | 31.15 | | | — | | | $ | — | | | Shares granted | | 25,790 | | | 42.00 | | | — | | | — | | | 25,790 | | | 42.00 | | | — | | | — | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | End of the period balance | | 48,900 | | | $ | 36.87 | | | — | | | $ | — | | | 48,900 | | | $ | 36.87 | | | — | | | $ | — | |
|